CorMedix Inc.CRMD
Price (close)
$7.85
Market cap
$611.9M
P/E
3.3x
Revenue (TTM)
$462.2M
Net income
$187.2M
Dividend yield
—
1-year total return
-29.4%
Net margin
40.5%
Revenue growth
280.5%
Debt / equity
—
What CorMedix Inc. does.
is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions.
Our primary focus has been commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis
team, commercial platform and increased the commercial portfolio with six marketed, hospital- and clinic-focused infectious disease products,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $239,231 | $190,936 | $65,408 | — | $43.5M | $311.7M |
| Net income | -$22.0M | -$28.2M | -$29.7M | -$46.3M | -$17.9M | $163.1M |
| Free cash flow | -$22.1M | -$22.6M | -$24.6M | -$38.7M | -$50.7M | $172.8M |
More on CRMD.
- CorMedix Inc. summary
- CorMedix Inc. financial statements
- CorMedix Inc. key metrics
- CorMedix Inc. health scores and style box
- CorMedix Inc. earnings
- CorMedix Inc. dividends
- CorMedix Inc. valuation
- CorMedix Inc. ownership and insiders
- CorMedix Inc. peers
Figures from CorMedix Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.